Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.84
INCY's Cash to Debt is ranked higher than
55% of the 1493 Companies
in the Global Biotechnology industry.

( Industry Median: 48.04 vs. INCY: 0.84 )
INCY' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 0.84

Equity to Asset -0.05
INCY's Equity to Asset is ranked higher than
50% of the 1113 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. INCY: -0.05 )
INCY' s 10-Year Equity to Asset Range
Min: -1.83   Max: 0.84
Current: -0.05

-1.83
0.84
F-Score: 4
Z-Score: 11.25
M-Score: -2.19
WACC vs ROIC
3.58%
48.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.93
INCY's Operating margin (%) is ranked higher than
85% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -79.37 vs. INCY: 1.93 )
INCY' s 10-Year Operating margin (%) Range
Min: -4064.53   Max: 9.05
Current: 1.93

-4064.53
9.05
Net-margin (%) -5.66
INCY's Net-margin (%) is ranked higher than
80% of the 1195 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. INCY: -5.66 )
INCY' s 10-Year Net-margin (%) Range
Min: -4565.45   Max: 7.67
Current: -5.66

-4565.45
7.67
ROA (%) -4.30
INCY's ROA (%) is ranked higher than
82% of the 1497 Companies
in the Global Biotechnology industry.

( Industry Median: -22.65 vs. INCY: -4.30 )
INCY' s 10-Year ROA (%) Range
Min: -70.43   Max: 5.19
Current: -4.3

-70.43
5.19
ROC (Joel Greenblatt) (%) 16.58
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 1457 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. INCY: 16.58 )
INCY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4727.38   Max: 47.33
Current: 16.58

-4727.38
47.33
Revenue Growth (3Y)(%) 59.60
INCY's Revenue Growth (3Y)(%) is ranked higher than
97% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. INCY: 59.60 )
INCY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -61.4   Max: 194.1
Current: 59.6

-61.4
194.1
EPS Growth (3Y)(%) -42.00
INCY's EPS Growth (3Y)(%) is ranked higher than
57% of the 824 Companies
in the Global Biotechnology industry.

( Industry Median: -4.80 vs. INCY: -42.00 )
INCY' s 10-Year EPS Growth (3Y)(%) Range
Min: -45.1   Max: 64.9
Current: -42

-45.1
64.9
» INCY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

INCY Guru Trades in Q2 2014

Ken Fisher 12,225 sh (New)
Louis Moore Bacon 100,000 sh (New)
Vanguard Health Care Fund 9,591,143 sh (+95.66%)
George Soros Sold Out
Mariko Gordon 23,728 sh (-78.93%)
» More
Q3 2014

INCY Guru Trades in Q3 2014

Jim Simons 97,916 sh (New)
Mariko Gordon 25,283 sh (+6.55%)
Vanguard Health Care Fund 10,174,343 sh (+6.08%)
Mariko Gordon 16,500 sh (unchged)
Louis Moore Bacon Sold Out
Ken Fisher 7,545 sh (-38.28%)
» More
Q4 2014

INCY Guru Trades in Q4 2014

Jim Simons 244,800 sh (+150.01%)
Ken Fisher 14,870 sh (+97.08%)
Vanguard Health Care Fund 10,174,343 sh (unchged)
Mariko Gordon Sold Out
» More
Q1 2015

INCY Guru Trades in Q1 2015

Ken Fisher 14,870 sh (unchged)
Vanguard Health Care Fund 10,174,343 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Incyte Corp

Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.
According to GuruFocus Insider Data, the recent CFO sales were: Aramark, Incyte Corp Ltd. and Facebook Inc. Read more...
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN
According to GuruFocus Insider Data, the largest insider sells during the past week were: Aramark, Incyte Corp Ltd, Emeritus Corp, and Huntsman Corp. Read more...

Ratios

vs
industry
vs
history
Forward P/E 84.03
INCY's Forward P/E is ranked higher than
87% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 84.03 )
N/A
P/S 32.63
INCY's P/S is ranked higher than
62% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 40.71 vs. INCY: 32.63 )
INCY' s 10-Year P/S Range
Min: 7.19   Max: 209.75
Current: 32.63

7.19
209.75
PFCF 828.38
INCY's PFCF is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 828.38 )
INCY' s 10-Year PFCF Range
Min: 7.24   Max: 941.29
Current: 828.38

7.24
941.29
POCF 371.34
INCY's POCF is ranked higher than
88% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 371.34 )
INCY' s 10-Year POCF Range
Min: 7.19   Max: 732.11
Current: 371.34

7.19
732.11
EV-to-EBIT 1732.00
INCY's EV-to-EBIT is ranked higher than
88% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 1732.00 )
INCY' s 10-Year EV-to-EBIT Range
Min: -3055.7   Max: 3083.6
Current: 1732

-3055.7
3083.6
Current Ratio 3.07
INCY's Current Ratio is ranked higher than
66% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.49 vs. INCY: 3.07 )
INCY' s 10-Year Current Ratio Range
Min: 1.51   Max: 21.14
Current: 3.07

1.51
21.14
Quick Ratio 3.06
INCY's Quick Ratio is ranked higher than
68% of the 1464 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. INCY: 3.06 )
INCY' s 10-Year Quick Ratio Range
Min: 1.51   Max: 21.14
Current: 3.06

1.51
21.14
Days Inventory 47.62
INCY's Days Inventory is ranked higher than
95% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. INCY: 47.62 )
INCY' s 10-Year Days Inventory Range
Min: 46.41   Max: 323.15
Current: 47.62

46.41
323.15
Days Sales Outstanding 43.73
INCY's Days Sales Outstanding is ranked higher than
89% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 141.98 vs. INCY: 43.73 )
INCY' s 10-Year Days Sales Outstanding Range
Min: 12.25   Max: 6447.52
Current: 43.73

12.25
6447.52

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.41
INCY's Price/Median PS Value is ranked higher than
78% of the 1656 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. INCY: 1.41 )
INCY' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 7.26
Current: 1.41

0.1
7.26
Earnings Yield (Greenblatt) 0.10
INCY's Earnings Yield (Greenblatt) is ranked higher than
85% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. INCY: 0.10 )
INCY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.3
Current: 0.1

0.1
1.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:ICY.Germany,
Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 
Weekly CFO Sells Highlight: Pandora Media Inc, Incyte Corp Ltd, Google Inc, American Airlines Group Feb 24 2014 
Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd. Sep 22 2013 
Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE Sep 15 2013 
Weekly CEO Sells Highlight: DIS, LMT, INCY, ADBE May 14 2012 
Weekly Top Insider Buys: VTR, INCY, FULT, HMA, CMC Jan 23 2012 
04 stocks with insider buying of more than $1.5 million since beginning of 2012 Jan 22 2012 
Weekly CFO Sales Highlight: EPIQ, INCY, AVB, JOSB, PCS, FLO Jun 12 2011 

More From Other Websites
INCYTE CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2015
15 biotech stocks to put on your watch list now May 15 2015
An Attractive M&A Play In The Busy Biotech Space May 13 2015
INCYTE CORP Financials May 06 2015
Biopharmaceutical Company Incyte Hires Steven Lerner as CIO May 05 2015
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers May 04 2015
Incyte Posts Wider-than-Expected Q1 Loss, Jakafi Grows - Analyst Blog May 04 2015
10-Q for Incyte Corp. May 03 2015
Incyte (INCY) Earnings Report: Q1 2015 Conference Call Transcript Apr 30 2015
Incyte reports 1Q loss Apr 30 2015
Incyte reports 1Q loss Apr 30 2015
Incyte Corp Earnings Call scheduled for 8:00 am ET today Apr 30 2015
Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical... Apr 30 2015
INCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 30 2015
Q1 2015 Incyte Corp Earnings Release - 07:00 am ET Apr 30 2015
Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical... Apr 30 2015
3 Stable Large-Cap Biotech Stocks to Buy Now - Analyst Blog Apr 29 2015
Incyte to Present at Upcoming Investor Conferences Apr 23 2015
Incyte to Present at Upcoming Investor Conferences Apr 23 2015
Will Agenus (AGEN) Disappoint in Q1 Earning Season? - Analyst Blog Apr 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK